Hydromorphone does not influence the immune response in patients affected by chronic pain
doi: 10.7417/CT.2013.1539
di
S. Coaccioli, L. Di Cato, A. Panaccione, M.E. Crapa, A. Paladini, A. Piroli, F. Marinangeli
Hydromorphone (HMP) is a semisynthetic opioid that has been
widely used over many years in the treatment of chronic moderatesevere
pain. A number of studies have demonstrated the use of HMP
in patients with cancer pain as safe and affective, and more recently
HMP has been also utilised in the treatment of chronic degenerative
pain (CDP). Then, some opioids are able to influence several immune
parameters. Aim of our study was to assess HMP in patients with CDP
in terms of safety and efficacy, to evaluate effects of HMP, within 2
months of observation, on cutaneous cell-mediated immunity (CCMI)
as well as other basic immune parameters, and the production of
interleukin-2 (IL-2) and interleukin-6 (IL-6). Results have shown that
HMP does not influence CCMI nor the sieric levels of immunoglobulins
or other immune parameters. Furthermore, it also has no effects
on the 3rd and 4th complement fractions, on white blood cells count
and T-lymphocyte subpopulations, on presence of seric autoantibodies,
nor on production of IL-2 and IL-6. Therapy with HMP has not
effects on the studied parameters of the immune system and does not
seem to have any influence on the immune competence and immune
response in patients with chronic pain. Clin Ter 2013; 164(2):e97-99.
doi: 10.7417/CT.2013.1539
ATTENZIONE: per accedere al servizio
di consultazione online dei file pdf occorre essere
abbonati alla rivista ed aver abilitato il propriopin.
Se non siete ancora abbonati potete abbonarvi e ricevere il pin attraverso
il nostro online
store.
Per l'attivazione del pin ricevuto, contattare ordini@seu-roma.it.
